IN FOCUS FEATURE
FROM OUR WEB SITE
Hundreds of North Carolinians research and manufacture vaccines at 14 companies across the state.
From Our Web Site
Pfizer Buys Serenex
Serenex's oral compound to fight cancer, its drug discovery technology, and its small molecule library have been sold to Pfizer Inc.
Sigma Xi Names New Leader
Jerome F. Baker, currently chief executive officer of the Federation of Animal Science Societies (FASS) in Savoy, Ill., will begin work at the scientific research society on April 14.
Jet Fuel Studies Bring Hamner Institutes $655,000
A grant from the Navy is giving the Hamner Institutes funding to study the effects of jet fuel vapors.
Addrenex Files Hypertension NDA
Addrenex Pharmaceuticals has filed a new drug application for its CloniBID™ product, which treats hypertension.
Federal Funds Power Novozymes Cellulosic Ethanol Research
The United States Department of Energy has selected Novozymes to develop the enzymes for a system to turn non-food products of agriculture into fuel.
Attagene Technology Profiled in Online Journal
Attagene's technology to look at genes currently active in a cell is highlighted in a Nature research journal.
In Focus
Vaccines: A Ton of Prevention
Though North Carolina’s biotechnology profile continues to grow in a variety of sectors, few have given the state the economic shot in the arm that is coming from vaccine research, development and manufacturing.
One reason North Carolina may be so well-positioned to take advantage of the dramatic upswing in vaccine demand is that the state already has a solid core of trained workers, researchers and companies engaged in finding and producing effective ways to prevent disease.
Read about the work being done on vaccines across North Carolina in this week's In Focus.
News from Other Sites
CED losing its leader in May
Monica Doss' 22 years of leadership at the Council for Entrepreneurial Development are coming to an end.
From the Raleigh News & Observer
Community Watch
- Dr. William R. Kelce, vice president, preclinical and early clinical development for Pozen Inc., has been appointed adjunct associate professor in the Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine. More
- Tranzyme Pharma has commenced dosing in a Phase I study of TZP-102, the company’s second generation, orally-administered treatment for mild-to-moderate gastroparesis and possibly other chronic gastrointestinal disorders. More.
- Two bioscience company executives were named to Triangle Business Leader magazine’s 2008 Impact Business Leaders of the Triangle. Stan Eskridge, CEO and president of Entegrion, and Donald Holzworth, chairman and CEO of The Constella Group made the list of 24 distinguished professionals. More
- Aldagen Inc. named David P. Carberry as its Chief Financial Officer. More.
- Raleigh-based DARA BioSciences has appointed Pacific Biopharma Associates President David J. Drutz, M.D., to its board of directors. More.
Please send Community Watch items to Jim Shamp.
Save the Date
Mar. 26-27
NC Nanotechnology Conference
(Winston-Salem)
Apr. 16-18
Venture 08
(Durham)
May 19-20
Biotech 2008
(Winston-Salem)
June 17-20
BIO 2008 Conference
NC Pavilion Sponsorship
(San Diego)
View our complete listing of events across North Carolina.
This newsletter was sent Thursday, Mar. 6, 2008. For the latest North Carolina biotechnology industry headlines, please visit the news section of our Web site.
Online subscription management is now available. Please respond to this e-mail if you cannot change your preferences online.